The Medicines and Healthcare products Regulatory Agency (MHRA) has today (14 August 2026) approved vimseltinib (romvimza) to treat adult patients with tenosynovial giant cell tumour (TGCT) when it impacts movement or where surgery is not an option. TGCT is a rare non-cancerous tumour that forms around a joint and tendons. It usually affects a single joint, most often the knee or ankle of young and middle-aged […]